دورية أكاديمية
Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061
| العنوان: | Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061 |
|---|---|
| المساهمون: | Eric Van Cutsem, Mayur Amonkar, Charles S Fuchs, Maria Alsina, Mustafa Özgüroğlu, Yung-Jue Bang, Hyun Cheol Chung, Kei Muro, Eray Goekkurt, Al B Benson 3rd, Weijing Sun, Zev A Wainberg, Josephine M Norquist, Xinqun Chen, Chie-Schin Shih, Kohei Shitara, Chung, Hyun Cheol |
| بيانات النشر: | Springer-Verlag Tokyo |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Antibodies, Monoclonal, Humanized / administration & dosage, Humanized / therapeutic use, Antineoplastic Agents, Immunological / administration & dosage, Immunological / therapeutic use, Antineoplastic Combined Chemotherapy Protocols, Belgium, Esophagogastric Junction, Humans, Neoplasm Metastasis, Progression-Free Survival, Quality of Life, Stomach Neoplasms / drug therapy, Stomach Neoplasms / mortality, Stomach Neoplasms / pathology, Surveys and Questionnaires, Chemotherapy, Gastric cancer, HRQoL, Pembrolizumab |
| الوصف: | Background: In the primary analysis population (i.e., PD-L1 combined positive score [CPS] ≥ 1) of the phase 3 KEYNOTE-061 study (NCT02370498), pembrolizumab did not significantly prolong overall survival or progression-free survival. Pembrolizumab had a favorable safety profile in the all-patient population. We present results of prespecified health-related quality of life (HRQoL) analyses. Methods: HRQoL was measured using the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30), EORTC QLQ gastric cancer questionnaire (QLQ-STO22), and EuroQol 5-dimension, 3-level questionnaire (EQ-5D-3L). Data were analyzed from patients who received ≥ 1 dose of study treatment and who completed ≥ 1 HRQoL assessment. Key analyses included baseline to week 12 least-squares mean (LSM) change in global health status (GHS)/QoL, functional/symptom subscales, and time to deterioration (TTD; ≥ 10-point decrease from baseline) for specific subscales. Results: The HRQoL population included 371 patients (pembrolizumab, n = 188; paclitaxel, n = 183). Compliance and completion rates for all 3 questionnaires were similar in both groups at baseline and week 12. There was no difference in LSM change between groups (- 3.54; 95% CI - 8.92 to 1.84) in GHS/QoL at week 12. LSM change from baseline to week 12 for most QLQ-C30, QLQ-STO22, and EQ-5D-3L subscales indicated some worsening of QoL in both groups. TTD for GHS/QoL, nausea/vomiting, and appetite loss subscales in QLQ-C30 and the pain subscales in QLQ-STO22 were similar between treatment groups. Conclusions: In this population with advanced gastric and GEJ cancer receiving second-line treatment, HRQoL was similar in patients receiving pembrolizumab and those receiving paclitaxel. Clinical trial registry and number: ClinicalTrials.gov, NCT02370498. ; open |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 1436-3291 1436-3305 |
| العلاقة: | GASTRIC CANCER; J00916; OAK-2022-04767; https://ir.ymlib.yonsei.ac.kr/handle/22282913/190695Test; T9992022100; GASTRIC CANCER, Vol.24(6) : 1330-1340, 2021-11 |
| DOI: | 10.1007/s10120-021-01200-w |
| الإتاحة: | https://doi.org/10.1007/s10120-021-01200-wTest https://ir.ymlib.yonsei.ac.kr/handle/22282913/190695Test |
| حقوق: | CC BY-NC-ND 2.0 KR |
| رقم الانضمام: | edsbas.50A07C2D |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 14363291 14363305 |
|---|---|
| DOI: | 10.1007/s10120-021-01200-w |